IMJUDO
As listed in the register: IMJUDO
20 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tremelimumab
- Made by
- Astrazeneca Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (IMJUDO). It describes the substance, not this exact product.
CTLA-4 is a negative regulator of T-cell activity.
Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T-cell activation.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-31
Safety of the active substance
From the US prescribing label for the same active substance (IMJUDO). It describes the substance, not this exact product.
Most common adverse reactions (≥ 20%) of patients with uHCC are rash, diarrhea, fatigue, pruritus, musculoskeletal pain, and abdominal pain.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Astrazeneca Canada Inc |
|---|---|
| Active substance | Tremelimumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | solution |
| Classification | L01FX20 · Cancer treatments and immune-system medicines |
| Route | intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02541009 |
| DPD drug code | 102967 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.